Similar articles for PMID: 29715119

Year	Number of Results
2009	1
2010	4
2011	2
2012	4
2013	2
2014	12
2015	19
2016	25
2017	36
2018	39
2019	17
2020	28
2021	24
2022	10
2023	1
2024	0

1

Eribulin Promotes Antitumor Immune Responses in Patients with Locally Advanced or Metastatic Breast Cancer.

Goto W, Kashiwagi S, Asano Y, Takada K, Morisaki T, Fujita H, Takashima T, Ohsawa M, Hirakawa K, Ohira M. Goto W, et al. Anticancer Res. 2018 May;38(5):2929-2938. doi: 10.21873/anticanres.12541. Anticancer Res. 2018. PMID: 29715119

2

Use of Tumor-infiltrating lymphocytes (TILs) to predict the treatment response to eribulin chemotherapy in breast cancer.

Kashiwagi S, Asano Y, Goto W, Takada K, Takahashi K, Noda S, Takashima T, Onoda N, Tomita S, Ohsawa M, Hirakawa K, Ohira M. Kashiwagi S, et al. PLoS One. 2017 Feb 6;12(2):e0170634. doi: 10.1371/journal.pone.0170634. eCollection 2017. PLoS One. 2017. PMID: 28166544 Free PMC article.

3

Mesenchymal-epithelial Transition and Tumor Vascular Remodeling in Eribulin Chemotherapy for Breast Cancer.

Kashiwagi S, Asano Y, Goto W, Takada K, Takahashi K, Hatano T, Tanaka S, Takashima T, Tomita S, Motomura H, Ohsawa M, Hirakawa K, Ohira M. Kashiwagi S, et al. Anticancer Res. 2018 Jan;38(1):401-410. doi: 10.21873/anticanres.12236. Anticancer Res. 2018. PMID: 29277801

4

Study on the progression types of cancer in patients with breast cancer undergoing eribulin chemotherapy and tumor microenvironment.

Kashiwagi S, Tsujio G, Asano Y, Goto W, Takada K, Takahashi K, Morisaki T, Fujita H, Takashima T, Tomita S, Ohsawa M, Hirakawa K, Ohira M. Kashiwagi S, et al. J Transl Med. 2018 Mar 9;16(1):54. doi: 10.1186/s12967-018-1443-5. J Transl Med. 2018. PMID: 29523158 Free PMC article.

5

Efficacy and safety of eribulin in patients with locally advanced or metastatic breast cancer not meeting trial eligibility criteria: a retrospective study.

Iizumi S, Shimoi T, Tsushita N, Bun S, Shimomura A, Noguchi E, Kodaira M, Yunokawa M, Yonemori K, Shimizu C, Fujiwara Y, Tamura K. Iizumi S, et al. BMC Cancer. 2017 Dec 4;17(1):819. doi: 10.1186/s12885-017-3846-8. BMC Cancer. 2017. PMID: 29202787 Free PMC article.

6

Effect of Eribulin With or Without Pembrolizumab on Progression-Free Survival for Patients With Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: A Randomized Clinical Trial.

Tolaney SM, Barroso-Sousa R, Keenan T, Li T, Trippa L, Vaz-Luis I, Wulf G, Spring L, Sinclair NF, Andrews C, Pittenger J, Richardson ET 3rd, Dillon D, Lin NU, Overmoyer B, Partridge AH, Van Allen E, Mittendorf EA, Winer EP, Krop IE. Tolaney SM, et al. JAMA Oncol. 2020 Oct 1;6(10):1598-1605. doi: 10.1001/jamaoncol.2020.3524. JAMA Oncol. 2020. PMID: 32880602 Free PMC article. Clinical Trial.

7

Prognostic Implications of Tumor-Infiltrating Lymphocytes in Association With Programmed Death Ligand 1 Expression in Early-Stage Breast Cancer.

Park IH, Kong SY, Ro JY, Kwon Y, Kang JH, Mo HJ, Jung SY, Lee S, Lee KS, Kang HS, Lee E, Joo J, Ro J. Park IH, et al. Clin Breast Cancer. 2016 Feb;16(1):51-8. doi: 10.1016/j.clbc.2015.07.006. Epub 2015 Aug 6. Clin Breast Cancer. 2016. PMID: 26364145

8

PD-L1 expression of the residual tumor serves as a prognostic marker in local advanced breast cancer after neoadjuvant chemotherapy.

Chen S, Wang RX, Liu Y, Yang WT, Shao ZM. Chen S, et al. Int J Cancer. 2017 Mar 15;140(6):1384-1395. doi: 10.1002/ijc.30552. Int J Cancer. 2017. PMID: 27925176 Free article.

9

Utility of Follow-up With Absolute Lymphocyte Count in Patients Undergoing Eribulin Treatment for Early Detection of Progressive Advanced or Metastatic Breast Cancer.

Goto W, Kashiwagi S, Takada K, Asano Y, Morisaki T, Shibutani M, Tanaka H, Hirakawa K, Ohira M. Goto W, et al. Anticancer Res. 2022 Feb;42(2):939-946. doi: 10.21873/anticanres.15553. Anticancer Res. 2022. PMID: 35093893

10

Effect of eribulin on patients with metastatic breast cancer: multicenter retrospective observational study in Taiwan.

Rau KM, Ou-Yang F, Chao TC, Kuo YL, Cheng TF, Chao TY, Chen DR, Tzeng YD, Wang BW, Liu CY, Hu MH, Lu YC, Ou WJ, Kuo CH, Chuang CH, Kan JY, Chen FM, Hou MF. Rau KM, et al. Breast Cancer Res Treat. 2018 Aug;170(3):583-591. doi: 10.1007/s10549-018-4778-y. Epub 2018 Apr 5. Breast Cancer Res Treat. 2018. PMID: 29623575 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

203 results

Results by year